FDA
-
-
-
-
-
-
-
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico
-
-
-
-
-
-
-
Pluristem Therapeutics (PSTI) Completes Patient Enrollment in Phase I Hematology Study Evaluating PLX-R18
-
-
-
-
-
-
-
Pluristem Therapeutics (PSTI) Reports FDA Clearance for IND Application for Phase II COVID-19 Study
-
-
-
-
-
-
-
Pluristem Therapeutics (PSTI) Reports Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
-
-
-
-
-
-
-
Pluristem Therapeutics (PSTI) and U.S. Dept. of Defense Highlight Positive Data from Studies Testing PLX-R18 as Prophylactic Treatment for Acute Radiation Syndrome
-
-
-
-
-
-
-
After-Hours Movers 04/03: (REPH) (TST) (CBLK) Higher; (NSPR) (AVEO) (SGMO) (more...)
-
-
-
-
-
-
-
Pluristem Therapeutics Recaps Key Opinion Leader Meeting on Peripheral Artery Disease (PAD)
-
251,598 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All